Pharmaceutical

Seventy-Eight Percent of Pediatricians Talk to Kids About Social Media and Mental Health: Is Your Child at Risk?

NEW YORK, June 17, 2024 /PRNewswire/ -- A new survey from SSCG Media Group, Omnicom Health Group's healthcare media center of…

5 months ago

Anju Showcases Advanced eClinical Suite at DIA Global Annual Meeting 2024

FORT LAUDERDALE, Fla., June 17, 2024 /PRNewswire/ -- Anju Software, a trailblazer in comprehensive data and information management solutions for…

5 months ago

Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2024 Financial Results

Revenues increased 14% in Q4 2024 compared to Q4 2023Gross profit margin improved 3% in FY 2024 compared to FY…

5 months ago

Labcorp Launches Global Trial Connect to Accelerate Clinical Trials

Suite of digital and data solutions designed to improve clinical trial efficiency, reduce data delays and simplify investigator site workflows…

5 months ago

iTeos and GSK Initiate GALAXIES Lung-301 Phase 3 Study, Assessing Belrestotug and Dostarlimab in Previously Untreated, Unresectable Locally Advanced / Metastatic PD-L1 Selected Non-Small Cell Lung Cancer

WATERTOWN, Mass. and GOSSELIES, Belgium, June 17, 2024 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS) (“iTeos”), a clinical-stage biopharmaceutical…

5 months ago

Curium Continues to Make Strong Progress in European Roll-Out Of PYLCLARI® – 18F-PSMA PET Diagnostics of Patients With Prostate Cancer

First doses of PYLCLARI® administered in Austria in early May 2024PYLCLARI® now available in France, Germany, Greece, Italy, and the…

5 months ago

Rothamsted Research Grants Yield10 Bioscience an Exclusive, Global Commercial License to Advanced Technology for Producing Omega-3 Products in Camelina

Engineered Camelina is intended to enable the land-based production of omega-3 oils used in aquafeed, petfood and human nutritionWOBURN, Mass.…

5 months ago

Aerovate Therapeutics Announces 24-Week Topline Results from the Phase 2b Portion of IMPAHCT Evaluating AV-101 for the Treatment of Pulmonary Arterial Hypertension

AV-101 did not meet the primary endpoint of change in pulmonary vascular resistance (PVR) for any of the studied dosesWALTHAM,…

5 months ago